This is a working overview of Aggregation, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-26. Anything still debated is marked as such rather than presented as settled.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
1993/638) Dunfermline and Kirkcaldy Districts (Mossmorran) Boundaries Amendment Order 1993 (S.I. 1993/639) Dumfries and Galloway and Strathclyde Regions and Cumnock and Doon Valley and Stewartry Districts (Loch Doon) Boundaries Amendment Order 1993 (S.I. 1993/640) Law Reform (Miscellaneous Provisions) (Scotland) Act 1990 (Commencement No. 11) Order 1993 (S.I. 1993/641) National Health Service (Travelling Expenses and Remission of Charges) (Scotland) Amendment Regulations 1993 (S.I. 1993/642) Glasgow Polytechnic and The Queen's College, Glasgow (Closure) (Scotland) Order 1993 (S.I. 1993/643) Local Authorities Etc. (Allowances) (Scotland) Amendment Regulations 1993 (S.I. 1993/644) Assured Tenancies (Rent Information) (Scotland) Amendment Order 1993 (S.I. 1993/645) Rent Officers (Additional Functions) (Scotland) Amendment Order 1993 (S.I. 1993/646) Rent Regulation (Forms and Information etc.) (Scotland) Amendment Regulations 1993 (S.I. 1993/647) Assured Tenancies (Forms) (Scotland) Amendment Regulations 1993 (S.I. 1993/648) Assured Tenancies (Rent Book) (Scotland) Amendment Regulations 1993 (S.I. 1993/649) Social Security (Payments on account, Overpayments and Recovery) Amendment Regulations 1993 (S.I. 1993/650) Local Government Finance (Housing) (Consequential Amendments) Order 1993 (S.I. 1993/651) Rent Officers (Additional Functions) (Amendment) Order 1993 (S.I. 1993/652) Rent Assessment Committees (England and Wales) (Amendment) Regulations 1993 (S.I. 1993/653) Assured Tenancies and Agricultural Occupancies (Forms) (Amendment) Regulations 1993 (S.I.
=== Safety === Like for other radioactive imaging agents in medicine, the applied amounts of radioactivity are so low that radiation-related adverse effects are very unlikely to occur, and have not been observed in practice. Consistent with the "tracer principle", the amount of pharmacologically active compound injected to a patient in the course of such an examination is extremely low. Adverse events, such as toxicity or allergic reactions, are thus highly improbable. No adverse or clinically detectable pharmacologic effects were observed following intravenous administration of 68Ga-Trivehexin when administered to cancer patients, and there were no significant changes in vital signs, laboratory study results, or electrocardiograms. In a study involving healthy volunteers, researchers again reported no adverse or clinically detectable pharmacologic effects and no significant changes in vital signs.
=== North America === United States: US president Donald Trump declared his intent to take over the Gaza Strip, relocate its Palestinian inhabitants, and redevelop it into the "Riviera of the Middle East", although members of Trump's administration walked back on elements of the plan. The US's takeover of the Gaza Strip was supported by 15% of Americans, with 62% expressing opposition. US Senator Rand Paul wrote, "We have no business contemplating yet another occupation to doom our treasure and spill our soldiers' blood." Organizations such as Arab Americans for Trump and the Uncommitted National Movement criticized Trump's proposal.
Although it was once thought that Alzheimer's disease can occur without neurofibrillary tangles in the neocortex, newer methods have shown that dementia in these cases can be linked to a comorbid condition, often Lewy body disease. Aβ plaques are dense, mostly insoluble deposits of amyloid beta peptide and cellular material outside and around neurons. Neurofibrillary tangles are aggregates of the microtubule-associated protein tau which has become hyperphosphorylated and accumulates inside neurons. Although many older individuals develop some plaques and tangles as a consequence of aging, the brains of people with Alzheimer's disease have a greater number of them in specific brain regions.
Eliminate the streptococcus – a course of penicillin is usually given at diagnosis to definitively clear any remaining streptococci (and avoid spread of a rheumatogenic clone), but there is no evidence that it makes any difference to the course of the illness. Treat the movement disorder Immunosuppression Prevention of relapses and further cardiac damage Manage the disability - Occupational therapy and physiotherapy are useful for maintaining function and muscle tone.
Sources: en.wikipedia.org
== Origin == GHRH is released from neurosecretory nerve terminals of these arcuate neurons, and is carried by the hypothalamo-hypophyseal portal system to the anterior pituitary gland, where it stimulates growth hormone (GH) secretion by stimulating the growth hormone-releasing hormone receptor. GHRH is released in a pulsatile manner, stimulating similar pulsatile release of GH. In addition, GHRH promotes slow-wave sleep directly. Growth hormone is required for normal postnatal growth, bone growth, regulatory effects on protein, carbohydrate, and lipid metabolism.
== Medical uses == Brimonidine is indicated for the lowering of intraocular pressure in people with open-angle glaucoma or ocular hypertension. It is also used to reduce redness of the eye. The gel is indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. A 2017 Cochrane review found insufficient evidence to determine if brimonidine slows optic nerve damage.
The three substrates of this enzyme are L-cystine, reduced nicotinamide adenine dinucleotide (NADH) and a proton. Its products are L-cysteine and oxidised NAD+. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-cysteine:NAD+ oxidoreductase. Other names in common use include cystine reductase (NADH), NADH-dependent cystine reductase, cystine reductase (NADH2), and NADH2:L-cystine oxidoreductase. This enzyme participates in cysteine metabolism.
Tris, or tris(hydroxymethyl)aminomethane, or known during medical use as tromethamine or THAM, is an organic compound with the formula (HOCH2)3CNH2. It is extensively used in biochemistry and molecular biology as a component of buffer solutions such as in TAE and TBE buffers, especially for solutions of nucleic acids. It contains a primary amine and thus undergoes the reactions associated with typical amines, e.g., condensations with aldehydes. Tris also complexes with metal ions in solution. In medicine, tris (known as tromethamine) is occasionally used as a drug, given in intensive care for its properties as a buffer for the treatment of severe metabolic acidosis in specific circumstances. Some medications are formulated as the "tromethamine salt" including Hemabate (carboprost as trometamol salt), and "ketorolac trometamol". In 2023 a strain of Pseudomonas hunanensis was found to be able to degrade TRIS buffer. Since Tris's pKa is more strongly temperature dependent, its use is not recommended in biochemical applications requiring consistent pH over a range of temperatures. Moreover, the temperature dependence of the pKa (and in turn buffer solution pH) makes pH adjustment difficult. (E.g., the 'room temperature' pH adjustment would not translate to 'measurement conditions' pH, unless care is taken to calculate the effect of temperature, see below.)
Sources: en.wikipedia.org
=== TruD === TruD is able to modify a variety of RNA, and it is unclear how these different RNA substrates are recognized. PUS 7 modifies U2 snRNA at the position 35 and this modification will increase when the cells are in heat shock. Another modification is cytoplasmic tRNA in position 13, and position 35 in pre-tRNATyr. PUS 7 modifies almost specificity does not depend on the type of RNA as mRNA show pseudouridylated by PUS 7. Recognize this the sequence of the RNA, UGUAR with the second U being the nucleotide that will be modified. The pseudouridylation of mRNA by PUS 7 increases during heat shock, because the protein moves from the nucleus to the cytoplasm. The modification is thought to increase the stability of mRNA during heat shock before the RNA goes to the nucleus or mitochondria, but more studies are needed.
In March 2010, the Center for Public Integrity released a report that Bush's administration had made more than 900 false pretenses in a two-year period about the alleged threat of Iraq against the United States, as his rationale to engage in war in Iraq.
== Interactions == The combination of piperacillin and tazobactam, commonly branded as Zosyn, improves their overall bactericidal activity as amino-benzylpenicillins and ureidopencillins work synergistically with β-lactamase inhibitors. Concurrent use or unregulated dosages of piperacillin results in increasing levels of piperacillin within the body, prolonging neuromuscular transmission blockages created by non-depolarizing muscle relaxants, and disruptions in urine tests for glucose. Some compounds that may interfere with the bactericidal activity of piperacillin include chloramphenicol, macrolides, and sulfonamides. Following two studies conducted in 1986 and 2006, piperacillin was found to inhibit the removal of methotrexate in animal kidneys. Furthermore, in the presence of piperacillin-tazobactam, the decay time for methotrexate triples in comparison to the normal half-life, leaving the patient exposed to cytotoxic effects produced by the chemical agent. While penicillin antibiotics generally work synergistically with aminoglycosides by enhancing their penetration of bacterial membranes, they can also work adversely by inactivating them. A reformulation of ethylenediaminetetraacetic acid and piperacillin-tazobactam has produced results showing an increase in their affinity with amikacin and gentamicin in vitro, enabling the process of simultaneous Y-site infusion to occur. However, tobramycin was found to be incompatible as a combination through Y-site infusion.
The riding drew headlines in the 2025 federal election, as it was initially called for the Bloc Québécois, but its recount led to Liberal candidate Tatiana Auguste winning by a margin of one vote, the narrowest result in the country. One voter in the district had her ballot returned as undeliverable due to an incorrect postal code printed on the pre-addressed ballot return envelope from Elections Canada; had her vote for the Bloc Québécois candidate been counted, the result would have been tied. After Elections Canada stated that it did not have legal standing to overturn the judicial recount, the Bloc Québécois announced it would be asking the Superior Court of Quebec for a new by-election to be held. On October 27, the court ruled that a byelection would not be held. On November 3, Sinclair-Desgagné announced that she would be appealing the ruling to the Supreme Court of Canada. On February 13, 2026, the Supreme Court annulled the result of the election in the riding, triggering a federal by-election. The by-election was held in April 2026, with Auguste winning by a margin of 731 votes, keeping the seat in Liberal control.
Senator Harkin complained, "One of the purposes of this center was to investigate and validate alternative approaches. Quite frankly, I must say publicly that it has fallen short. I think quite frankly that in this center and the office previously before it, most of its focus has been on disproving things rather than seeking out and approving." Members of the scientific community criticized this comment as showing Harkin did not understand the basics of scientific inquiry, which tests hypotheses, but never intentionally attempts to "validate approaches". In 2009, the NCCAM's yearly budget was increased to about $122 million. Overall NIH funding for CAM research increased to $300 million by 2009. By 2009, Americans were spending $34 billion annually on CAM. In 2012, the Journal of the American Medical Association (JAMA) published a criticism that NCCAM had funded study after study, but had "failed to prove that complementary or alternative therapies are anything more than placebos".
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.